UroGen Pharma Ltd. (URGN) Return on equity 2016–2021
UroGen Pharma Ltd. (URGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-1317.2%FY2021 · since FY2016: -11.9% → -1317.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2021 | -1317.2% | -1183.9 pp |
| FY2020 | -133.3% | -75.0 pp |
| FY2019 | -58.3% | +25.7 pp |
| FY2018 | -84.0% | -54.8 pp |
| FY2017 | -29.2% | -17.3 pp |
| FY2016 | -11.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice